Literature DB >> 28905517

The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension.

Libo Chen1,2, Carolyn M Larsen1, Rachel J Le1, Heidi M Connolly1, Sorin V Pislaru1, Joseph G Murphy1, Michael D McGoon1, Robert P Frantz1, Garvan C Kane1.   

Abstract

INTRODUCTION: Tricuspid valve regurgitation (TR) is a frequent finding in patients with pulmonary arterial hypertension (PAH). However, its prognostic significance and relation to PAH, while suspected, are poorly understood. We assessed 727 consecutive patients with newly diagnosed PAH who underwent transthoracic echocardiographic evaluation of tricuspid valve function.
OBJECTIVES: The study objective was to determine the association of TR presence and severity with patient characteristics, pulmonary artery hemodynamics and outcome.
METHODS: Consecutive patients with newly diagnosed PAH (N = 727 with group 1 pulmonary hypertension) underwent transthoracic echocardiographic evaluation of tricuspid valve function at diagnosis. The primary study end point was all-cause mortality or lung transplantation.
RESULTS: In this population, 702 patients (96.5%) had TR; in 165 patients (23%), TR was severe. Compared with those with no or mild TR by echocardiography criteria, patients with severe TR had shorter mean (SD) 6-minute walk distances (285 [125] m vs 360 [121] m; P = .02) and higher levels of B-type natriuretic peptide (695 [672] pg/dL vs 328 [300] pg/dL; P < .05). Severe TR was associated with greater right atrial dilatation (91% vs 47%; P = .004) and right ventricular (RV) dilatation (92% vs 51%; P = .008), greater right atrial pressure (mean [SD] 15 [7] mm Hg vs 10 [6] mm Hg; P < .001) and lower cardiac index (mean [SD], 2.2 [0.7] L/min/m2 vs 2.8 [0.9] L/min/m2; P < .001). Severe TR was strongly predictive of greater 5-year mortality risk after adjustment for age, sex, functional class, 6-minute walk distance, diffusing capacity, RV size and pulmonary vascular resistance index (adjusted hazard ratio, 1.83; 95% CI, 1.38-2.41; P < .001).
CONCLUSIONS: Severe TR was a significant predictor of long-term mortality rate in PAH, and TR severity correlated with PAH severity.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  echocardiography; prognosis; right heart failure; right ventricular function; tricuspid valve regurgitation

Mesh:

Year:  2017        PMID: 28905517     DOI: 10.1111/crj.12713

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  5 in total

1.  All Roads Lead to Rome: Diverse Etiologies of Tricuspid Regurgitation Create a Predictable Constellation of Right Ventricular Shape Changes.

Authors:  Benjamin A Orkild; Brian Zenger; Krithika Iyer; Lindsay C Rupp; Majd M Ibrahim; Atefeh G Khashani; Maura D Perez; Markus D Foote; Jake A Bergquist; Alan K Morris; Jiwon J Kim; Benjamin A Steinberg; Craig Selzman; Mark B Ratcliffe; Rob S MacLeod; Shireen Elhabian; Ashley E Morgan
Journal:  Front Physiol       Date:  2022-06-02       Impact factor: 4.755

2.  ERS International Congress, Madrid, 2019: highlights from the Clinical Techniques, Imaging and Endoscopy Assembly.

Authors:  Julia d'Hooghe; Haizea Alvarez Martinez; Pia Iben Pietersen; Christian B Laursen; Nicole Hersch; Ádám Domonkos Tárnoki; Simon Walsh; Jouke Annema; Daniela Gompelmann
Journal:  ERJ Open Res       Date:  2020-07-20

Review 3.  Exercise Right Heart Catheterisation in Cardiovascular Diseases: A Guide to Interpretation and Considerations in the Management of Valvular Heart Disease.

Authors:  Felipe H Valle; Basma Mohammed; Stephen P Wright; Robert Bentley; Neil P Fam; Susanna Mak
Journal:  Interv Cardiol       Date:  2021-02-15

4.  Risk assessment in PAH using quantitative CMR tricuspid regurgitation: relation to heart catheterization.

Authors:  Erik Hedström; Anna Bredfelt; Göran Rådegran; Håkan Arheden; Ellen Ostenfeld
Journal:  ESC Heart Fail       Date:  2020-05-06

5.  Impact of pulmonary hypertension on outcome in patients with moderate or severe tricuspid regurgitation.

Authors:  Sahrai Saeed; Jenna Smith; Karine Grigoryan; Stig Urheim; John B Chambers; Ronak Rajani
Journal:  Open Heart       Date:  2019-10-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.